Vassiliki Karantza, associate vice president of MSD Research Laboratories, said: “At MSD, we are committed to driving research forward for innovative modalities in earlier stages of cancer, where we can have the most meaningful impact on patients.
Denial of responsibility! Yours Bulletin is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – admin@yoursbulletin.com. The content will be deleted within 24 hours.